Also, the authors studied the expression of claudin-2, an important positive modulator of breast cancer liver metastasis, showing that the knockdown of individual SFK members, including Yes and Fyn, induced Claudin-2 expression, while contrary to this, Lyn-selective kinase inhibitor, bafetinib (INNO-406), reduced Claudin-2 expression and suppressed breast cancer liver metastasis [72]. Here, CLDN2 is linked to breast carcinoma.